3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Lung Neoplasms
4
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Rheumatoid Arthritis, Systemic Juvenile
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Periodic Fevers Syndrome
1
Pancreatic Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mevalonate Kinase Deficiency
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Melanoma
1
Leukemia, Myelomonocytic, Chronic
1
Intestinal Neoplasms
1
Gastrointestinal Neoplasms
1
Cryopyrin-Associated Periodic Syndromes
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Clonal Cytopenia of Undetermined Significance
1
Carcinoma, Renal Cell
1
Carcinoma, Ductal
1
Carcinoma
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Arthritis, Juvenile
1
Arthralgia
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
pembrolizumab
287
Nivolumab
258
Ipilimumab
236
Cyclophosphamide
135
aldesleukin
134
Interleukin-2
104
Temozolomide
75
Dacarbazine
74
trametinib
70
Vemurafenib
69
fludarabine
68
dabrafenib
65
fludarabine phosphate
62
sargramostim
44
binimetinib
44
Radiosurgery
44
Biopsy
43
Paclitaxel
42
Bevacizumab
42
incomplete Freund's adjuvant
39
encorafenib
37
Radiotherapy
36
Cisplatin
36
CTLA-4 Antigen
36
atezolizumab
35
Carboplatin
35
Magnetic Resonance Spectroscopy
33
cobimetinib
32
Specimen Handling
31
Introns
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Melanoma
×
canakinumab
×
Clear all
NCT03484923
2024-06-18
PLATforM
Novartis
Phase 2
Completed
196 enrolled
22 charts